AIM ImmunoTech Reports Q3 2025 Financials and Highlights Progress in Pancreatic Cancer Program
ByAinvest
Tuesday, Nov 18, 2025 8:57 am ET1min read
AIM--
AIM ImmunoTech reported Q3 2025 financial results with cash, cash equivalents, and marketable investments of $2.4 million. Research and development expenses were $607,000, and general and administrative expenses were $1.8 million. The net loss from operations was $3.3 million, or $(1.57) per share. The company highlighted positive clinical and operational execution, with a focus on its pancreatic cancer clinical program.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet